Inclusion criteria encompassed all studies employing in vitro models (e.g., fibroblast proliferation, keratinocyte migration, collagen synthesis assays), in vivo studies using animal models for wound healing assessments, clinical trials evaluating the efficacy and safety of tripeptides in human subjects, and studies utilizing molecular, biochemical, or histological analyses to determine the mechanisms of tripeptides in wound recovery
This novel dual-agonist approach surpassed the efficacy of monotherapy while maintaining a favorable costbenefit and safety profile [122]
stomach pain), and treatment discontinued if it is suspected
Machiraju, P., Wang, X., Sabouny, R., Huang, J., Zhao, T., Iqbal, F., King, M., Prasher, D., Lodha, A., Jimenez-Tellez, N., Ravandi, A., Argiropoulos, B., Sinasac, D., Khan, A., Shutt, T
Zero human trials
Heres why its reliable